Histogen Inc. (HSTO)
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
$939.79K
Dr. Stephen J. Mento Ph.D.
22.00
San Diego, CA
Jul 25, 2013
-0.08
$-2.81
3.39
4.05
-62,793.33%
-0.10
-0.00
0.17
62.65
4.05
-161.92%
-108.33%
Similar stocks (12)
Aileron Therapeutics, Inc.
ALRN
Tempest Therapeutics, Inc.
TPST
Curis, Inc.
CRIS
Tonix Pharmaceuticals Holding Corp.
TNXP
Senti Biosciences, Inc.
SNTI
Cingulate Inc.
CING
Sonnet BioTherapeutics Holdings, Inc.
SONN
Palisade Bio, Inc.
PALI
Artelo Biosciences, Inc.
ARTL
TRACON Pharmaceuticals, Inc.
TCON
NexImmune, Inc.
NEXI
Better Therapeutics, Inc.
BTTX
Similar stocks (12)
Aileron Therapeutics, Inc.
ALRN
Tempest Therapeutics, Inc.
TPST
Curis, Inc.
CRIS
Tonix Pharmaceuticals Holding Corp.
TNXP
Senti Biosciences, Inc.
SNTI
Cingulate Inc.
CING
Sonnet BioTherapeutics Holdings, Inc.
SONN
Palisade Bio, Inc.
PALI
Artelo Biosciences, Inc.
ARTL
TRACON Pharmaceuticals, Inc.
TCON
NexImmune, Inc.
NEXI
Better Therapeutics, Inc.
BTTX